What is IgGenix?
IgGenix is dedicated to pioneering novel antibody-based therapies for immunological conditions, with a primary focus on allergies. The company leverages its proprietary SEQ SIFTER antibody discovery platform to engineer treatments that offer effective clinical responses for both pediatric and adult patient populations. Their lead candidate, IGNX001, is a first-in-class antibody designed to disrupt the allergic cascade, specifically targeting food allergies. Through rigorous research and clinical trials, IgGenix aims to advance its pipeline and provide much-needed therapeutic solutions in the allergy and immunology space.
How much funding has IgGenix raised?
IgGenix has raised a total of $65M across 2 funding rounds:
Series A
$25M
Series B
$40M
Series A (2021): $25M with participation from ShangBay Capital, Matthias Westman, Alexandria Venture Investments, AllerFund, and Khosla Ventures
Series B (2023): $40M led by Khosla Ventures and Eli Lilly and Company Pvt
Key Investors in IgGenix
Khosla Ventures
Khosla Ventures is a prominent venture capital firm that provides strategic advice and funding to entrepreneurs developing breakthrough technologies. Their investment focus is broad, encompassing areas such as AI, fintech, health, and sustainable energy, making them a key backer for innovative companies like IgGenix.
Eli Lilly and Company Pvt
Eli Lilly and Company Pvt, a subsidiary of the global biopharmaceutical giant, specializes in developing advanced treatment options for chronic diseases. Their investment in IgGenix highlights a strategic interest in novel therapies for immunological conditions and allergy treatments.
ShangBay Capital
ShangBay Capital is a venture capital firm with a specialization in medical devices and biotechnology. Their early-stage investment in IgGenix indicates a focus on companies with innovative platforms poised to make significant advancements in healthcare.
What's next for IgGenix?
The recent major strategic investment in IgGenix signals a pivotal moment for the company, likely enabling an acceleration of its clinical development pipeline and expansion of its research initiatives. This capital infusion is expected to support the advancement of IGNX001 through further clinical trials and potentially broaden the company's therapeutic focus within immunological diseases. IgGenix's strategic positioning in the allergy and immunology market, coupled with its innovative antibody discovery platform, suggests a strong potential for future growth and market impact as it moves towards commercialization.
See full IgGenix company page
